Who are Alemtuzumab (GZ402673)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Alemtuzumab infusion, FluCAM [Fludara + Campath], MabCampath-1h.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alemtuzumab-gz402673.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Alemtuzumab (GZ402673) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alemtuzumab (GZ402673) (Alemtuzumab (GZ402673)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (CD52 antagonist). Area: Immunology / Hematology.

marketed Monoclonal antibody (CD52 antagonist) CD52 Immunology / Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Alemtuzumab (GZ402673) (Alemtuzumab (GZ402673)) — Genzyme, a Sanofi Company. Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Alemtuzumab (GZ402673) TARGET	Alemtuzumab (GZ402673)	Genzyme, a Sanofi Company	marketed	Monoclonal antibody (CD52 antagonist)	CD52
Alemtuzumab infusion	Alemtuzumab infusion	Johns Hopkins University	marketed	monoclonal antibody (CD52-directed)	CD52
FluCAM [Fludara + Campath]	FluCAM [Fludara + Campath]	Genzyme, a Sanofi Company	phase 3	Combination chemotherapy and monoclonal antibody	Ribonucleotide reductase / DNA polymerase (fludarabine); CD52 (alemtuzumab)
MabCampath-1h	MabCampath-1h	University of British Columbia	phase 3	Monoclonal antibody (CD52 antagonist)	CD52

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (CD52 antagonist) class)

Genzyme, a Sanofi Company · 1 drug in this class
University of British Columbia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alemtuzumab (GZ402673) — Competitive Intelligence Brief. https://druglandscape.com/ci/alemtuzumab-gz402673. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab